How well does a new lung fibrosis medication work in everyday patients

This is a real-world study of nerandomilast, an oral medication designed to slow lung function decline in people with idiopathic pulmonary fibrosis (a scarring lung disease) or progressive pulmonary fibrosis. The study watches how the medication works in everyday patients at multiple hospitals in Israel—people who may be older or have other health conditions, unlike participants in earlier research trials. Researchers will compare how fast your lungs were declining before you started this treatment with how they change afterward.

Earlier research showed promise for this medication in carefully selected patients, but doctors wanted to know whether it works as well in real-world patients who are older or sicker or taking other medicines. This study answers that question by observing everyday practice.